ANR.AX - Anatara Lifesciences Limited

ASX - ASX Delayed Price. Currency in AUD
0.755
+0.045 (+6.34%)
At close: 4:10PM AEST
Stock chart is not supported by your current browser
Previous Close0.710
Open0.715
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.710 - 0.770
52 Week Range0.575 - 1.830
Volume182,856
Avg. Volume90,381
Market Cap37.307M
Beta-0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.061
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.27
  • When Will Anatara Lifesciences Limited (ASX:ANR) Become Profitable?
    Simply Wall St.2 months ago

    When Will Anatara Lifesciences Limited (ASX:ANR) Become Profitable?

    Anatara Lifesciences Limited’s (ASX:ANR): Anatara Lifesciences Limited engages in the development of non-antibiotic oral solutions for gastro intestinal diseases in animals and humans in Australia. The AU$41.51M market-cap posted aRead More...

  • ABN Newswire2 months ago

    Anatara Lifesciences Ltd (ASX:ANR) CEO, Dr Mel Bridges Announces Retirement

    Brisbane, Australia, May 17, 2018 - (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR.AX - News) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation. With the planned change of focus toward developing the Company's human pipeline in gastrointestinal health, a search has commenced to augment the Board with further expertise in this area.

  • ABN Newswire2 months ago

    Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation on Zoetis Exclusive Global License

    Brisbane, Australia, May 16, 2018 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive ...

  • Anatara Announces Exclusive Global License Agreement with Zoetis
    Business Wire2 months ago

    Anatara Announces Exclusive Global License Agreement with Zoetis

    Anatara Lifesciences is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach® as a non-antibiotic approach to aid in the control of diarrhoeal disease in livestock and in horses.

  • ABN Newswire2 months ago

    Anatara Lifesciences Ltd (ASX:ANR) Exclusive Global License Agreement with Zoetis

    Brisbane, Australia, May 15, 2018 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR.AX - News) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

  • ABN Newswire3 months ago

    Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

    Brisbane, Australia, April 19, 2018 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018. Anatara Lifesciences is pleased ...